ILKAP Activators
ILKAP activators emerge as influential agents that modulate the function of ILKAP, facilitating its role as a mediator in various cellular pathways. These activators influence ILKAP's interactions, stabilizing it and enhancing its involvement in crucial biological processes. Through their actions, ILKAP activators guide the enzyme in its selective dephosphorylation activities, ensuring that the cellular machinery involved in growth, survival, and response to environmental cues operates with precision and balance. ILKAP (Integrin-Linked Kinase-Associated Serine/Threonine Phosphatase) is a remarkable enzyme that resides at the crossroads of numerous cellular pathways, dictating cellular functions such as cell cycle progression, apoptosis, and various signal transduction pathways. Integral to cell communication and response mechanisms, ILKAP works diligently, modulating signals to ensure that cells operate optimally, preserving cellular integrity and function.
Focusing on the regulatory domain of ILKAP, these activators ensure that the phosphatase can optimally interact with its substrates and associated proteins, like Integrin-Linked Kinase (ILK). By doing so, the activators aid in fine-tuning the cellular responses governed by ILKAP, ensuring that signals are modulated appropriately to maintain cell cycle continuity, and appropriate cellular responses are initiated in scenarios such as cellular stress.
Emphasizing the importance of the molecular architecture of ILKAP, these activators align themselves to facilitate the protein's functional expressions. Their presence augments ILKAP's natural propensity to maintain a harmonious cellular environment through its regulatory influences, embodying a profound essence of cellular modulation and control that echoes through the realms of cellular life, influencing vitality and cellular orchestration.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic acid, as an HDAC inhibitor, could enhance ILKAP expression by promoting a more relaxed chromatin structure, facilitating gene transcription. VPA might enhance the accessibility of the ILKAP gene to transcriptional machinery, potentially increasing its expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A could potentially increase ILKAP expression by inhibiting HDAC activity, leading to hyperacetylation of histones. This modification may enhance the transcription of genes like ILKAP, involved in cellular signaling pathways. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid could promote ILKAP expression by altering chromatin conformation and facilitating transcription factor binding to the ILKAP gene promoter region, enhancing its transcription. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate may improve ILKAP expression by inhibiting HDACs, facilitating a more transcriptionally active chromatin state and promoting gene expression relevant to cellular signaling and adhesion. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus could affect ILKAP expression by modulating the mTOR pathway, potentially altering cellular responses like growth, survival, and apoptosis, where ILKAP might play a role. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 might affect ILKAP expression or activity by specifically targeting mTOR, potentially modulating pathways where ILKAP acts as a regulatory phosphatase. | ||||||